← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
EcoR1 Capital, LLC
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001587114
Purchase history
- Companies traded
- 5
- Purchases · 12M
- 2
- Purchases · 24M
- 18
- Average purchase
- $7.9M
- Median purchase
- $2.6M
- Gross purchase value
- $142.6M
Companies: ANAPTYSBIO, INC | Aktis Oncology, Inc. | Atara Biotherapeutics, Inc. | Zymeworks Inc. | iTeos Therapeutics, Inc.
18 SEC accession(s) · 10 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-05-11 | Atara Biotherapeutics, Inc. | ATRA | 10% Owner | $4.7M | Open filing |
| 2026-01-12 | Aktis Oncology, Inc. | AKTS | Director | $40.0M | Open filing |
| 2025-05-19 | Zymeworks Inc. | ZYME | Director | 10% Owner | $635.5K | Open filing |
| 2025-05-16 | iTeos Therapeutics, Inc. | ITOS | 10% Owner | $38.7M | Open filing |
| 2025-04-18 | Zymeworks Inc. | ZYME | Director | 10% Owner | $1.5M | Open filing |
| 2025-04-07 | Zymeworks Inc. | ZYME | Director | 10% Owner | $3.6M | Open filing |
| 2025-04-02 | Zymeworks Inc. | ZYME | Director | 10% Owner | $1.5M | Open filing |
| 2025-03-27 | Zymeworks Inc. | ZYME | Director | 10% Owner | $1.2M | Open filing |
| 2025-03-24 | Zymeworks Inc. | ZYME | Director | 10% Owner | $1.6M | Open filing |
| 2025-03-19 | Zymeworks Inc. | ZYME | Director | 10% Owner | $2.9M | Open filing |
| 2025-03-13 | Zymeworks Inc. | ZYME | Director | 10% Owner | $13.1M | Open filing |
| 2025-01-21 | Zymeworks Inc. | ZYME | Director | 10% Owner | $2.0M | Open filing |
| 2025-01-15 | Zymeworks Inc. | ZYME | Director | 10% Owner | $2.3M | Open filing |
| 2025-01-10 | Zymeworks Inc. | ZYME | Director | 10% Owner | $3.0M | Open filing |
| 2025-01-02 | Zymeworks Inc. | ZYME | Director | 10% Owner | $5.3M | Open filing |
| 2025-01-02 | ANAPTYSBIO, INC | ANAB | Director | 10% Owner | $1.1M | Open filing |
| 2024-12-27 | Zymeworks Inc. | ZYME | Director | 10% Owner | $1.9M | Open filing |
| 2024-12-26 | Zymeworks Inc. | ZYME | Director | 10% Owner | $17.5M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small Sample | 5.6% (1/18) | 100.0% (1/1) | +4.3% | +4.3% | +4.3% |
| 20D | 1Small Sample | 5.6% (1/18) | 100.0% (1/1) | +11.6% | +11.6% | +11.6% |
| 60D | 1Small Sample | 5.6% (1/18) | 0.0% (0/1) | -10.3% | -10.3% | -10.3% |
| 120D | 0No Data | 0.0% (0/17) | — | — | — | — |
Research patterns
- First purchase in 12M
- 2/15
- Large purchase ≥ $100k
- 18/18
- Cluster buying · 15D
- 10/18
- Buying the dip
- 1/1
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.